Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedOF
Omega Funds
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $241.5M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionThird Arc Bio
Develops novel multifunctional antibodies for oncology and immunology & inflammation indications
$52MSeries A+
Role not disclosedCaldera Therapeutics
Develops bispecific antibody CLD-423 for inflammatory bowel disease
$37.5MSeries A1
Role not disclosed